BioNTech SE (NASDAQ:BNTX) is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an ...

A personalized mRNA vaccine paired with Keytruda may help keep skin cancer from returning after surgery, a large clinical trial suggests.

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of treatment that doctors hope will work against many types of tumors.

A new jab extended the length of time patients were cancer free, but it is unclear for how long.

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

The mRNA technology that built Moderna and BioNTech’s COVID-19 vaccines and is now being used to build cancer vaccines has ...

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move beyond one-time attacks and short-term memory to become a long-term immunity ...

NEW YORK, Jan. 27, 2026 /PRNewswire/ -- Cancer vaccine research is entering a new phase as leading scientists join forces to coordinate the next stage of progress in cancer immunity. Cancer Vaccine ...

Roles of ICD in enhancing antigen presentation by APCs. Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward ...

Global pharmaceutical companies Moderna and MSD announced on the 1st (local time) at the American Society of Clinical Oncology (ASCO) in Chicago, U.S., the results of a phase 2 clinical trial ...

mRNA technology is enabling an entirely new HIV vaccine strategy that, for the first time, successfully primes the immune system toward broadly neutralizing antibodies in humans. The TB vaccine ...

Cancer continues to be one of the deadliest non-communicable diseases in the world. Every year, the number of cases rises drastically even as medical care races to develop newer and more effective ...